chrisvoncsefalvay/vaers-outcomes huggingface dataset:
FLU LIKE SYMPTOMS; HEAVY CHESTED; CHILLS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN) dose was not reported, administered on 03-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 04-APR-2021, the subject experienced flu like symptoms. On 04-APR-2021, the subject experienced heavy chested. On 04-APR-2021, the subject experienced chills. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from chills, flu like symptoms, and heavy chested. This report was non-serious.
Severe muscle cramps in thighs with sciatic nerve pain / When walk there is muscle pain in upper thighs; trochanteric bursitis left hip/had some inflammation of the trochanteric bursa on the other side; had another bout of pain/Still have problems lying down ever since I took the 2nd shot; There was muscle pain in upper thighs/Myalgia lower body; This spontaneous case was reported by a consumer and describes the occurrence of SCIATICA (Severe muscle cramps in thighs with sciatic nerve pain / When walk there is muscle pain in upper thighs), GREATER TROCHANTERIC PAIN SYNDROME (trochanteric bursitis left hip/had some inflammation of the trochanteric bursa on the other side), PAIN (had another bout of pain/Still have problems lying down ever since I took the 2nd shot) and MYALGIA (There was muscle pain in upper thighs/Myalgia lower body) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 03821A) for COVID-19 prophylaxis.     Concurrent medical conditions included Interstitial lung disease (stable), Barrett's esophagus (mostly resolved-no lesions) and Thyroid disorder. Concomitant products included LEVOTHYROXINE for Thyroid disorder, SIMVASTATIN (STATIN [SIMVASTATIN]) for an unknown indication.    On 29-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced SCIATICA (Severe muscle cramps in thighs with sciatic nerve pain / When walk there is muscle pain in upper thighs), GREATER TROCHANTERIC PAIN SYNDROME (trochanteric bursitis left hip/had some inflammation of the trochanteric bursa on the other side), PAIN (had another bout of pain/Still have problems lying down ever since I took the 2nd shot) and MYALGIA (There was muscle pain in upper thighs/Myalgia lower body). At the time of the report, SCIATICA (Severe muscle cramps in thighs with sciatic nerve pain / When walk there is muscle pain in upper thighs), GREATER TROCHANTERIC PAIN SYNDROME (trochanteric bursitis left hip/had some inflammation of the trochanteric bursa on the other side), PAIN (had another bout of pain/Still have problems lying down ever since I took the 2nd shot) and MYALGIA (There was muscle pain in upper thighs/Myalgia lower body) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient thought the events might be from statins but liver enzymes were fine and stopped statins to test that no change reported. Patient was administered with steroid shot.
Tdap injection on 9-6-07, afternoon. Friday morning, I had pain in my shoulder above injection site, which radiated into my neck on the left side. Had pain on left side. Symptoms lasted ~ 4 days, improving gradually after 2 days. No treatment.
Narrative: COVID infection following completion of COVID vaccine series: 04/17/2021 COVID vaccine dose #1 05/12/2021 COVID vaccine dose #2 07/04/2021 Asymptomatic COVID positive per pre-op nasal swab test. Pt reported having close contact with son who was a known/suspected COVID case. 07/06/2021 Pt reported remaining asymptomatic
The patient began to have a rash, turning to splotchy hives. The patient's mother states the patient may have had slight difficulty breathing. The patient's temperature was 99.5.
possible NSTEMI or myocarditis cardiac cath, no stent needed. started on DAPT therapy for 1 year (clopidogrel and aspirin). along with atorvastatin and metoprolol discharged home
Patient has had ongoing diarrhea since 2/16/21.  3-4 episodes per day. Patient took otc immodium which has not made a difference.  Patient was encouraged to see primary care provider for prescription alternatives and to make sure to stay hydrated.
Flu-like symptoms: Chest congestion, Coughing, Wheezing, Head/sinus congestion, Muscle aches, Joint aches, Sore throat, Fatigue, Headache, Runny nose, Loss of appetite. Patient has continued taking his seasonal allergy medication (Zyrtec). Started Emergen-C supplements. Got additional bed rest (slept unusually long  12.5 hours from 10/03/13 to 9:30AM 10/04/13). Continues to take plenty of fluids.
7 days later, I developed a rash at the injection site. At this time (day 8) it's about 2 inches across, slightly raised, red, warm, and a little uncomfortable, but not itchy.
Fainted, low grade fever, muscle aches - neck, HA, clammy, lasted for 24 hours. Went to ER.
Chills, achy body, experiencing headaches for 3 days as well as fatigue still.
papular hive-like rash trunk & face extremities; rx Atarax syrup;
This spontaneous report has been received from a healthcare worker referring to unspecified number of patients. Concurrent condition and medical history were not reported. On unknown dates the patients were vaccinated with GARDASIL (dose, frequency and route not reported, lot # K008931, expired date: 04-MAR-2017). No adverse event were reported. This is one of the several reports from the same reporter. Additional information has been requested.
Fever on set aprox 6 hrs after injections > 103.5 lasted 6/28.6/29. 6/30.7/1 had febrile seizure lasting < 7 min.  looked ok after seizure
84 Y male with history of asthma/COPD overlap syndrome, obstructive sleep apnea, tobacco smoking, type 2 diabetes, atrial fibrillation, hypertension, chronic kidney disease, gout, who re-presented to the ED on 8/6 with increased generalized weakness after tested positive for COVID 8/5 and was admitted for further management of COVID pneumonia.   Patient had increased dry cough on 8/3 which improved with albuterol. He was evaluated in the ED on 8/5 and found to be COVID-positive. He had no hypoxia with ambulation and was subsequently discharged home. He re-presented to the ED on 8/6 with worsening generalized weakness. Last fever on 8/6. He was treated with remdesivir (8/6 to 8/8). He continued to show symptomatic improvement without hypoxia at rest or with ambulation. Hospital course was also significant for acute kidney injury 2/2 hypovolemia. Renal function returned to baseline with IV hydration. Patient was briefly hypertensive during this hospitalization, requiring increase of PTA hydralazine from QHS to BID.    Patient was clinically stable for discharged on 8/9 with COVID kit. Patient will continue to remain in self-isolation until 8/15.    Primary Procedures: None   Secondary Procedures: None   Reason for Hospital Admission (Admitting Diagnosis):  COVID-19 PNEUMONIA
When giving the vaccine the fluid came out of the hub and squirted on the patient's shirt and arm. Also there was liquid on the immunizer's hands. The immunizer said most did not get into the patient's arm, thus we revaccinated.
11AM inject site devel immed erythema of 3" diameter which over next few mins spread to 4" also minimal induration @ puncture site of needle; rx DPH;
Blood in phlegm,  cat scan, diagnosed with pneumonia and on an antibiotic.
This case was reported by a physician and described the occurrence of headache in a 52-year-old male subject who was vaccinated with Havrix, for prophylaxis. The subject's medical history included allergies, asthma, depression, restless legs syndrome, non-smoker and consumption of approximately one alcoholic beverage per week. Concurrent medications included Levoxyl, Effexor. Advair, Astelin, Mirapex and Trazodone. On 18 October 2006, the subject received 1st dose of Havrix. On 19 October 2006, one day after vaccination with Havrix, the subject experienced headache, feeling unwell, fatigue and excessive sleepiness. The subject was seen at a physician's office. The physician considered the events were clinically significant (or requiring intervention) and reported that the subject, "missed several days of work" as a result of the events. The immunization series with Havrix was discontinued. On 23 October 2006, laboratory analyses for complete blood count, metabolic function test, erythrocyte sedimentation rate, and C-reactive protein were all normal. The physician concluded from the laboratory analyses that there were " no obvious indicators of infection." At the time of follow-up reporting, 08 December 2006, the events had improved. The physician considered the events to be related to vaccination with Havrix.
- fever (101 degF+) x 1.5 days  - neck stiffness - chills - fatigue  - lymphadenopathy  - myalgia - arthralgia
12/10 pm:  Dizzy, Nausea 12/11: all day: Cold chills, nausea, upper arm - injection site: soreness, warm, hard center, redness  12/12:  All symptoms continued.  The injection site: soreness, warm, hard center, redness increased dramatically - spread to my entire upper arm.
Arrived at observation area at 3:56pm. Patient noted itching on top of hands within minutes of injection. No erythema in creases or abdomen. Lungs clear, throat normal, airway patent. 4:03pm itching worse, but no rash noted on exam. 4:06 25mg benadryl PO. 4:10 reexam, no visible rash, redness or distress in or on arms, hands, chest or abdomen. Denied itching in femoral creases. 4:15 no rash, but feels better, no itching. Patient admits to a hx of anxiety now. 4:25 patient feels good to go. Last exam no rash, redness, itching or distress.
Patient was given second dose of Moderna vaccine instead of Pfizer. Patient was scheduled for an appointment with a Provider on 04/22/2021
Patient reports muscle soreness at the left arm, where she received her Shingrix shot,  that lasted for from Sept 2 to Dec 2019. She said the pain just went away a couple of days ago. She described it as a deep ache in the muscle (similar to a toothache kind of pain). She said that she did not notice any swelling or redness at the site at any time. She did not treat the pain with any medication to relieve it. She said she didn't do anything that would have caused the pain.
pt recv vax & exp fever, which may have been as high as 104 to 105 which lasted for more than 24hr;pt also exp infrequent rash;
Janssen COVID-19 Vaccine EUA. I had a red spot appear in my left eye on 4/10. On 4/11 my fever increased to 101 and it felt as if I had a severe case of the flu. On 4/12 I felt fatigued, no fever. No appetite each day.  4/13 the injection site is still sore, red, and swollen.
This case was reported by a healthcare professional and described the occurrence of inappropriate dose of drug administration in an adult subject of unspecified gender who was vaccinated with Engerix B (GlaxoSmithKline) for prophylaxis.  On an unspecified date the adult subject received unspecified dose of Engerix B at 10 mcg.  This was considered to be an inappropriate dose of drug administered as the subject received a pediatric dose of Engerix B.  The subject was also found to have not responded to therapy.  This event was not resolved at the time of reporting.  This inappropriate dosing occurred in an undetermined number of adult patients.  The lot numbers of Engerix B administered were AHBV6B5AB and AHBVB166AA.
In the exact place that I received my shot my arm occasionally pulses rapidly. It never did that before. Sometimes my arm will go numb for a brief moment. The sensation will go down my arm too.
Increased shortness of breath for a few weeks and then acute worsening of this along with new chest tightness on 4/30 which led to hospitalization and ultimately diagnosis of pericarditis. Atrial fibrillation also developed during the course of the 4 day, 3 night hospitalization.
Erythema, warmth and tenderness at injection site - skin reaction, concern for cellulitis - put on Keflex (us seen reaction to immunization).
multiple migraines vs focal seizures  1-2/week which continue to this date.  Neurological evaluation including MRI, EEG, lab work completed.  Multiple migraine medications as well as seizure medications have been tried but symptoms continue.
my face felt warm and hot for a few days then woke up to redness, itchiness and a burning sensation, I couldn't touch my face without feeling like it was so sensitive
COVID-19 Vaccine Breakthrough Case: Hospitalization & Death  The case tested positive for COVID and went to the emergency room and was admitted on 10/9/21. The case unfortunately passed away on 10/20/21. The individual received a monoclonal antibody infusion on 10/9/21.   As part of his COVID-19 symptoms, the individual had difficulty breathing, loss of smell/taste, and a fever. The case also developed pneumonia and acute respiratory distress syndrome (ARDS).
Sick - throwing up, vomiting, and fever for five days and headaches, too. I didn't have any swelling lymph nodes. I thought I would have to go to the hospital. I didn't go to work on Monday or Tuesday. I was taking Pedialyte and water so I wouldn't dehydrate. I had had COVD before and it was light symptoms compared to this - it was only 12 hours or so. I still get random bad headaches and I have issues with my stomach with it getting upset with queasiness and runs - that comes and goes, too. Stomach pains. I didn't have any of this before - I have only had this since the second injection.
Itchy raised bumps appeared with red rash around area. Went away after about 10-15mins. Had about 7-8 @ a time. New ones appeared and went away for about 3 hours. Took a 25mg Benadryl tablet about a hour after started.
fatigue; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (fatigue) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced FATIGUE (fatigue). At the time of the report, FATIGUE (fatigue) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2022-440822, MOD-2022-441214 (Patient Link).
Lumps around injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site lump in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced injection site lump. On an unknown date, the outcome of the injection site lump was recovered/resolved.   It was unknown if the reporter considered the injection site lump to be related to Shingrix.  Additional details were provided as follows: The patient developed lumps around the injection site following dose 1 of Shingrix. The reporter consented to follow up. The health care professional could not provide complete patient demographics, lot number, or expiration date. The health care professional describes lumps as quarter sized and lumps completely resolved within seven days.
Itching at site of vaccination after 30 minutes  generalised itching and hives over upper body within 40 minutes given Benadryl 50 mg with relief
I am going through my third outbreak since having the vaccine/ suspected vaccination failure; third outbreak; extremely ill; stomach is raw; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, illness and stomach discomfort. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles, illness and stomach discomfort were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, illness and stomach discomfort to be related to Shingles vaccine.  Additional details were provided as follows: This case was reported by the patient. The age at vaccination was not reported. The patient had taken the shingles vaccine and was currently going through third outbreak since having the vaccine. The patient was extremely ill, and stomach was raw. The patient asked any advice. This case was considered to be a suspected vaccination failure case, as the details regarding completion of primary vaccination schedule, laboratory confirmation for shingles and time to onset were unknown.
Vomiting and diarrhea 11/13/02 to 11/18/02. Constipated and myalgia, anorexia 11/23/02 and vague abdominal discomfort. Diagnosed Diabetic mellitus juvenile on 11/23/02. Myositic and hepatitis 11/23/02.
Client received the first dose of Covid Vaccine on Jan 21, 2021, Moderna lot # 011L20A,  She returned to the clinic on Jan 29,2021, without her immunization card, and was given second dose too early at 8 days.  It was caught while she was still on site.  She was told not to receive any more Covid vaccinations.   Conatacted her on Feb 2, 2021.  She had a headache and fever for 2 days, and a sore arm.  She was feeling better but not 100%.  She had missed 2 days of work.
Pt received 3rd dose, had received a dose in January that was not told to the pharmacy staff.  Pt was given one dose on 6/26/21 and then 7/25/21.
Sore arm; This spontaneous case was reported by a patient and describes the occurrence of MYALGIA (Sore arm) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Sore arm). At the time of the report, MYALGIA (Sore arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ultrasound scan: normal (normal) No blood clots. On an unknown date, X-ray: normal (normal) No broken arms.         Concomitant medications were not provided by reporter.  Treatment information was not provided by reporter.   This case was linked to MOD-2021-286887 (Patient Link).
Information has been received from a county health registered nurse concerning a 7 year old female who on 12-MAR-2001 was vaccinated with varicella virus vaccine live (Oka/Merck). On 05-APR-2007, the patient developed varicella, < 50 lesions. The nurse reported that an outbreak of varicella had taken place in the local school district in April 2007, and this student was identified during the county health investigation. An immunization clinic was conducted in the school where students received a second dose of varicella virus vaccine live (Oka/Merck). This is one of 28 reports received from the same source. No further information is available.
This spontaneous report as received from a pharmacist via a company representative refers to an unknown age female patient. Pertinent medical history, drug allergies or reaction were not reported. In approximately December 2013/January 2014, reported as "within the last month", the patient was vaccinated with ZOSTAVAX, lot # J005849, expiration date: 17-AUG-2014, 0.65 ml, subcutaneous. Concomitant medication was not reported. On an unknown date, the patient experienced mild local reaction at injection site. The patient developed an itchy, red, tender "knot" with swelling at site of ZOSTAVAX injection. The patient sought medical attention. The patient's symptoms resolved within 4-5 days. Causality was not reported. This case is linked to the same reporter MARRS# 1401USA002531 and 1401USA003340. Additional information has been requested.
This spontaneous report as received from a physician and from a support services director refers to a patient of unknown age and gender. No information regarding the patient's medical history or concurrent conditions was provided. On 24-JUN-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 injection (lot# M006141, expiry date 28-MAY-2017; dose and route of administration were not reported). There were no concomitant therapies reported. The dose of the vaccine was exposed to two separate temperature excursion (dates unspecified): one lasting for 72 hours, with the lowest recorded temperature of 34 degrees Fahrenheit (-1.11 degrees Celsius) and the second one lasting for 32 hours, with the lowest recorded temperature of 33 degrees Fahrenheit (-0.56 degrees Celsius). The vaccine was stored in a refrigerator. No adverse effects were reported. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Pt had a local reaction on right thigh with 10cm induration and erythema. Pt stable.
Severe Joint Pain (ongoing), Heart Racing (ongoing), Shaking (ongoing), disrupted mensural cycle, canker sores (ongoing), nausea and upset stomach (ongoing), trouble sleeping (on going), back pain (2 weeks)
Administering only about 0.1ml to the patient.; Needle was defective; Product complaint; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced underdose (Verbatim: Administering only about 0.1ml to the patient.), needle issue (Verbatim: Needle was defective) and pharmaceutical product complaint (Verbatim: Product complaint).  The outcome of the underdose, needle issue and pharmaceutical product complaint were unknown.   Additional Information: GSK Receipt Date: 07-SEP-2023 The reporter reported that while administering Shingrix vaccine to the patient the needle was defective and leaked, administering only about 0.1 ml to the patient, which led to underdose and needle issue. The reporter did not consent to follow up.
Headache, Fever, NauseaVomiting, POSITIVE COVID Test 7/28/2021 @ 9:35AM Narrative: ED visit for testing for his employee per Employee Health protocol.